{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T04:54:44Z","timestamp":1771908884482,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jdiacomp.2017.01.011","type":"journal-article","created":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T22:49:06Z","timestamp":1485211746000},"page":"918-927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"31","author":[{"given":"Morten","family":"Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Sonne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian H.","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jdiacomp.2017.01.011_bb0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/138920011794520053","article-title":"Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: Metabolism and clinical practice","volume":"12","author":"Abe","year":"2011","journal-title":"Current Drug Metabolism"},{"issue":"24","key":"10.1016\/j.jdiacomp.2017.01.011_bb0010","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.jdiacomp.2017.01.011_bb0015","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA: The Journal of the American Medical Association"},{"issue":"Suppl. 1","key":"10.1016\/j.jdiacomp.2017.01.011_bb0020","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.2337\/dc15-S011","article-title":"8. Cardiovascular disease and risk management","volume":"38","author":"Association, A. D","year":"2015","journal-title":"Diabetes Care"},{"issue":"18","key":"10.1016\/j.jdiacomp.2017.01.011_bb0025","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.279.18.1458","article-title":"Persistence of use of lipid-lowering medications: A cross-national study","volume":"279","author":"Avorn","year":"1998","journal-title":"JAMA: The Journal of the American Medical Association"},{"issue":"18","key":"10.1016\/j.jdiacomp.2017.01.011_bb0030","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/archinte.168.18.1975","article-title":"Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects","volume":"168","author":"Bays","year":"2008","journal-title":"Archives of Internal Medicine"},{"issue":"9","key":"10.1016\/j.jdiacomp.2017.01.011_bb0035","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1016\/j.jdiacomp.2017.01.011_bb0040","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00125-011-2382-3","article-title":"Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: A randomised controlled study","volume":"55","author":"Beysen","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2017.01.011_bb0045","first-page":"708","article-title":"In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants","volume":"41","author":"Braunlin","year":"2000","journal-title":"Polymer Preprints"},{"issue":"4","key":"10.1016\/j.jdiacomp.2017.01.011_bb0050","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/hep.23831","article-title":"Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism","volume":"52","author":"Brufau","year":"2010","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"5","key":"10.1016\/j.jdiacomp.2017.01.011_bb0055","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.amjmed.2008.09.047","article-title":"Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006","volume":"122","author":"Cheung","year":"2009","journal-title":"The American Journal of Medicine"},{"issue":"18","key":"10.1016\/j.jdiacomp.2017.01.011_bb0065","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/j.jdiacomp.2017.01.011_bb0070","author":"FDA"},{"issue":"8","key":"10.1016\/j.jdiacomp.2017.01.011_bb0075","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc08-0283","article-title":"Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy","volume":"31","author":"Fonseca","year":"2008","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jdiacomp.2017.01.011_bb0080","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"10.1016\/j.jdiacomp.2017.01.011_bb0085","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2337\/diab.44.11.1303","article-title":"Albuminuria and poor glycemic control predict mortality in NIDDM","volume":"44","author":"Gall","year":"1995","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.jdiacomp.2017.01.011_bb0090","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4158\/endp.19.2.a38267720403k242","article-title":"AACE comprehensive diabetes management algorithm 2013","volume":"19","author":"Garber","year":"2013","journal-title":"Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists"},{"issue":"6","key":"10.1016\/j.jdiacomp.2017.01.011_bb0095","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-121-6-199409150-00004","article-title":"Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial","volume":"121","author":"Garg","year":"1994","journal-title":"Annals of Internal Medicine"},{"issue":"14","key":"10.1016\/j.jdiacomp.2017.01.011_bb0100","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/archinte.168.14.1531","article-title":"Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy","volume":"168","author":"Goldberg","year":"2008","journal-title":"Archives of Internal Medicine"},{"issue":"5","key":"10.1016\/j.jdiacomp.2017.01.011_bb0105","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11892-014-0482-4","article-title":"Bile acid sequestrants: Glucose-lowering mechanisms and efficacy in type 2 diabetes","volume":"14","author":"Hansen","year":"2014","journal-title":"Current Diabetes Reports"},{"issue":"6","key":"10.1016\/j.jdiacomp.2017.01.011_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001803","article-title":"Effect of bile acid sequestrants on glycaemic control: Protocol for a systematic review with meta-analysis of randomised controlled trials","volume":"2","author":"Hansen","year":"2012","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.01.011_bb0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1463-1326.2011.01486.x","article-title":"Effects of colesevelam on glucose absorption and hepatic\/peripheral insulin sensitivity in patients with type 2 diabetes mellitus","volume":"14","author":"Henry","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"11","key":"10.1016\/j.jdiacomp.2017.01.011_bb0120","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.01.011_bb0125","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.jdiacomp.2017.01.011_bb0130","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1055\/s-0031-1273770","article-title":"Comparison of efficacy of pitavastatin and colestimide in Japanese patients with diabetes mellitus complicated by hyperlipidemia and metabolic syndrome","volume":"119","author":"Kato","year":"2011","journal-title":"Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association"},{"issue":"11","key":"10.1016\/j.jdiacomp.2017.01.011_bb0135","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1111\/j.1572-0241.2002.07067.x","article-title":"Funding, disease area, and internal validity of hepatobiliary randomized clinical trials","volume":"97","author":"Kjaergard","year":"2002","journal-title":"The American Journal of Gastroenterology"},{"issue":"3","key":"10.1016\/j.jdiacomp.2017.01.011_bb0140","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1463-1326.2009.01159.x","article-title":"Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: A randomized double-blind placebo-controlled study","volume":"12","author":"Kondo","year":"2010","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.01.011_bb0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2125.1994.tb04239.x","article-title":"Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia","volume":"37","author":"Lyons","year":"1994","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1016\/j.jdiacomp.2017.01.011_bb0150","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2337\/dc11-2050","article-title":"Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and \u03b2-cell function","volume":"35","author":"Marina","year":"2012","journal-title":"Diabetes Care"},{"issue":"12 Suppl.","key":"10.1016\/j.jdiacomp.2017.01.011_bb0155","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1592\/phco.31.12.65S","article-title":"Managing special populations among patients with type 2 diabetes mellitus","volume":"31","author":"Marquess","year":"2011","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.jdiacomp.2017.01.011_bb0160","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4158\/EP12337.OR","article-title":"Diurnal glucose profiles using continuous glucose monitoring to identify the glucose-lowering characteristics of colesevelam HCl (Welchol)","volume":"19","author":"Mazze","year":"2013","journal-title":"Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists"},{"key":"10.1016\/j.jdiacomp.2017.01.011_bb0165","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"3","key":"10.1016\/j.jdiacomp.2017.01.011_bb0170","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1507\/endocrj.EJ11-0378","article-title":"Hypoglycemic effects of colestimide on type 2 diabetic patients with obesity","volume":"59","author":"Neda","year":"2012","journal-title":"Endocrine Journal"},{"issue":"14","key":"10.1016\/j.jdiacomp.2017.01.011_bb0175","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","article-title":"Rosiglitazone revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality","volume":"170","author":"Nissen","year":"2010","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.jdiacomp.2017.01.011_bb0180","first-page":"CD009361","article-title":"Colesevelam for type 2 diabetes mellitus","volume":"12","author":"Ooi","year":"2012","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.01.011_bb0185","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4158\/EP09146.OR","article-title":"Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy","volume":"16","author":"Rigby","year":"2010","journal-title":"Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists"},{"issue":"5","key":"10.1016\/j.jdiacomp.2017.01.011_bb0190","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1021\/js9603820","article-title":"Absorption, distribution and excretion of GT31-104, a novel bile acid sequestrant, in rats and dogs after acute and subchronic administration","volume":"86","author":"Rosenbaum","year":"1997","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"5","key":"10.1016\/j.jdiacomp.2017.01.011_bb0195","first-page":"348","article-title":"The glucose and lipid effects of colesevelam as monotherapy in drug-na\u00efve type 2 diabetes","volume":"46","author":"Rosenstock","year":"2014","journal-title":"Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et M\u00e9tabolisme"},{"issue":"13","key":"10.1016\/j.jdiacomp.2017.01.011_bb0200","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1055\/s-0034-1383648","article-title":"Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus","volume":"46","author":"Rosenstock","year":"2014","journal-title":"Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et M\u00e9tabolisme"},{"issue":"4","key":"10.1016\/j.jdiacomp.2017.01.011_bb0205","doi-asserted-by":"crossref","first-page":"629","DOI":"10.4158\/EP10130.OR","article-title":"Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes","volume":"16","author":"Rosenstock","year":"2010","journal-title":"Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists"},{"issue":"2","key":"10.1016\/j.jdiacomp.2017.01.011_bb0210","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/met.2009.0049","article-title":"The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: A pilot study","volume":"8","author":"Schwartz","year":"2010","journal-title":"Metabolic Syndrome and Related Disorders"},{"issue":"4","key":"10.1016\/j.jdiacomp.2017.01.011_bb0215","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2337\/db12-0923","article-title":"The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes","volume":"62","author":"Smushkin","year":"2013","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.jdiacomp.2017.01.011_bb0220","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1530\/EJE-14-0309","article-title":"Postprandial gallbladder emptying in patients with type 2 diabetes: Potential implications for bile-induced secretion of glucagon-like peptide 1","volume":"171","author":"Sonne","year":"2014","journal-title":"European Journal of Endocrinology\/European Federation of Endocrine Societies"},{"issue":"7258","key":"10.1016\/j.jdiacomp.2017.01.011_bb0225","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.01.011_bb0230","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jdiacomp.2011.11.008","article-title":"Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: An open-label, randomized, case\u2013control, crossover study","volume":"26","author":"Suzuki","year":"2012","journal-title":"Journal of Diabetes and its Complications"},{"issue":"4","key":"10.1016\/j.jdiacomp.2017.01.011_bb0235","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/SMJ.0b013e31819bd023","article-title":"Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia","volume":"102","author":"Takebayashi","year":"2009","journal-title":"Southern Medical Journal"},{"issue":"3","key":"10.1016\/j.jdiacomp.2017.01.011_bb0245","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"Reduction in incidence of coronary heart disease","volume":"251","author":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I","year":"1984","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jdiacomp.2017.01.011_bb0250","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","author":"The Lipid Research Clinics Coronary Primary Prevention Trial results. II","year":"1984","journal-title":"JAMA: The Journal of the American Medical Association"},{"issue":"7644","key":"10.1016\/j.jdiacomp.2017.01.011_bb0255","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.01.011_bb0260","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1507\/endocrj.K05-098","article-title":"Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia","volume":"54","author":"Yamakawa","year":"2007","journal-title":"Endocrine Journal"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.01.011_bb0265","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clinthera.2007.01.003","article-title":"Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes","volume":"29","author":"Zieve","year":"2007","journal-title":"Clinical Therapeutics"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716306493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716306493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T18:28:30Z","timestamp":1536085710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872716306493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1056872716306493"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.01.011","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}